IndustryCompany release

Solventum Q3 sales fall 7% on ERP order timing, but full-year EPS guidance raised

🇺🇸 Solventum Corp (SOLV) · Thu 05 Nov 2026

The medtech group reported $1.9bn in third-quarter sales as advance orders placed ahead of an ERP cutover reversed, while lifting its adjusted EPS outlook to $7.20-$7.30.

Solventum reported third-quarter 2026 results on 5 November, with sales of $1.9 billion. That was down 7.0% on a reported basis and 2.8% on an organic basis.

The company attributed the decline to the reversal of advance orders that customers placed in the second quarter ahead of an ERP system cutover. In other words, demand was pulled forward into Q2, which weighed on the following quarter.

Despite the weaker quarter, Solventum raised its full-year adjusted earnings-per-share guidance to $7.20-$7.30. It now expects organic growth toward the high end of its 2.5%-3.0% range, and it affirmed free cash flow of $200-300 million.

Separately, the company noted that it has received US FDA 510(k) clearance for the combined use of Restrata and V.A.C. Therapy in advanced wound care. A 510(k) clearance is the pathway by which the FDA clears devices shown to be substantially equivalent to a legally marketed device. No further details on the clearance were available in the material reviewed.

What it means for your team

  • Quality and supply-chain teams should note that ERP cutovers can distort order patterns, with customers stocking up beforehand and ordering less afterwards.
  • Regulatory affairs teams in wound care may wish to review the new 510(k) clearance covering combined Restrata and V.A.C. Therapy use.
  • Market-access teams should treat the Q3 decline as timing-related, according to the company, rather than a reported change in underlying demand.

Company's press release (SEC filing): Solventum Corp ↗

Article written by VigiEye from the official source (Solventum Corp). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →